Palvella Therapeutics Enhances Intellectual Property Portfolio
In an exciting development for Palvella Therapeutics, the U.S. Patent and Trademark Office has granted a sixth patent that adds substantial protection for its lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel. This patent underscores Palvella’s ongoing commitment to advancing innovative therapies for patients afflicted with serious, rare genetic skin diseases.
Significance of the Recent Patent
Broad Patent Coverage
The newly awarded patent No. 12,329,748 offers comprehensive coverage for anhydrous compositions of rapamycin and other mTOR inhibitors, such as temsirolimus and everolimus. With this significant intellectual property in place, Palvella is well-positioned to protect its proprietary products and formulations.
The Vision Behind QTORIN™ Rapamycin
CEO Wes Kaupinen emphasizes the importance of this patent in supporting the strategic direction of Palvella. He stated, "This milestone solidifies the exclusivity of QTORIN™ rapamycin, a key element of our broader strategy to maximize its long-term value through strong intellectual property and trade secrets in formulation and manufacturing."
Treatment Applications and Designations
QTORIN™ rapamycin has garnered Breakthrough Therapy, Orphan Drug, and Fast Track Designations from the FDA, specifically for the treatment of microcystic lymphatic malformations. These recognitions not only highlight the therapeutic potential of the product but also pave the way for possible seven-year market exclusivity upon approval.
Financial Support for Clinical Trials
Additionally, Palvella has received an FDA Orphan Products Grant, which could amount to $2.6 million in funding to support the ongoing SELVA Phase 3 clinical trial. This substantial financial backing is indicative of the FDA’s recognition of the critical need for effective treatments in the realm of rare skin disorders.
Palvella’s Continued Commitment to Rare Diseases
Founded by experts in rare disease drug development, Palvella Therapeutics is dedicated to creating groundbreaking therapies aimed at conditions for which there are currently no FDA-approved options. The company’s pipeline includes various product candidates derived from its patented QTORIN™ platform, targeting severe genetic skin ailments.
Current Clinical Trials
Currently, QTORIN™ rapamycin is under evaluation in two pivotal clinical trials: the Phase 3 SELVA trial, focusing on microcystic lymphatic malformations, and the Phase 2 TOIVA trial, which investigates cutaneous venous malformations. The outcomes of these trials could significantly influence the future of treatment options available to patients.
About Palvella Therapeutics
Palvella Therapeutics, trading under the ticker Nasdaq: PVLA, operates as a clinical-stage biopharmaceutical company. With a focus on the development and commercialization of novel therapeutics, Palvella aims to transform the lives of individuals suffering from rare genetic skin diseases through innovative solutions.
Frequently Asked Questions
What recent patent was granted to Palvella Therapeutics?
Palvella was granted a sixth U.S. patent for its QTORIN™ 3.9% rapamycin anhydrous gel, enhancing its intellectual property portfolio.
What does the new patent cover?
The patent covers a wide variety of anhydrous compositions of rapamycin and mTOR inhibitors, and methods of use related to dermatologic conditions.
What designations did QTORIN™ rapamycin receive from the FDA?
QTORIN™ rapamycin received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, reflecting its potential for treating rare diseases.
What financial support has Palvella received for its clinical trials?
Palvella Therapeutics was awarded an FDA Orphan Products Grant, which could amount to $2.6 million to assist with clinical trial funding.
How is QTORIN™ rapamycin currently being tested?
QTORIN™ rapamycin is being evaluated in the Phase 3 SELVA trial and the Phase 2 TOIVA trial, targeting conditions like lymphatic malformations and venous malformations, respectively.
